Citi analyst Hidemaru Yamaguchi upgraded Santen Pharmaceutical to Buy from Neutral with a price target of 1,400 yen, up from 1,100 yen. The analyst says the company’s restructuring-led profit recovery is not yet priced into the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly